X

Drug Profile

Research programme: SDX 101 second generation analogues - Salmedix

Latest Information Update: 30 May 2007

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Salmedix
Class
Mechanism of Action Apoptosis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

30 May 2007 Discontinued - Preclinical for Cancer in USA (PO)
16 Jun 2005 Salmedix has been acquired by Cephalon
20 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the adverse events and Cancer pharmacodynamics sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com